scispace - formally typeset
Open AccessJournal ArticleDOI

Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors.

R. Charlier
- 01 Aug 1970 - 
- Vol. 39, Iss: 4, pp 668-674
Reads0
Chats0
TLDR
It is concluded that the cardiac actions of amiodarone are not produced by competitive blockade of β‐adrenoceptors.
Abstract
1. The cardiac actions of amiodarone, a benzofuran derivative used in the treatment of angina pectoris, have been compared with those of (±)-propranolol in anaesthetized dogs. 2. After three successive intravenous injections of propranolol, 0·5 mg/kg, had reduced the heart rate by 25%, a fourth dose had no further negative chronotropic action, but amiodarone, 10 mg/kg intravenously, at this point reduced the heart rate by 23%. 3. Amiodarone, 10 mg/kg intravenously, reduced, but did not abolish, cardiac responses to isoprenaline, 2 μg/kg intravenously. Subsequent successive injections of 10 mg/kg of amiodarone did not further block the responses to isoprenaline, but propranolol, 1 mg/kg intravenously, abolished them. 4. Amiodarone reduced cardiac chronotropic and inotropic responses to glucagon, which were not affected by propranolol. 5. Cardiac output was increased 5 min after amiodarone, 10 mg/kg intravenously, but at 10 min and thereafter it did not differ from control values. Propranolol, 1 mg/kg intravenously, reduced cardiac output by 17% at 5 min, and by 30% after 30 min. 6. From this and other evidence which is discussed, it is concluded that the cardiac actions of amiodarone are not produced by competitive blockade of β-adrenoceptors.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

TL;DR: It is concluded that amiodarone is effective for long-term therapy of recurrent ventricular tachyarrhythmias, that induction of arrhythmia during therapy does not always predict efficacy, and that side effects are frequent but do not usually limit therapy.
Journal ArticleDOI

Clinical efficacy of amiodarone as an antiarrhythmic agent

TL;DR: Amiodarone proved safe in patients with severe congestive heart failure and severe myocardial damage and liberates patients from a rigid hourly schedule and provides for continuous antiarrhythmic control, days and even weeks after treatment is discontinued.
Journal ArticleDOI

A third class of anti-arrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474

TL;DR: It was concluded that direct depression of depolarization could have contributed little to the protection against ouabain‐induced fibrillation, and it is suggested that this effect contributes to anti‐arrhythmic activity.
Journal ArticleDOI

Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study

TL;DR: This trial demonstrated a significant reduction in cardiac mortality and ventricular arrhythmias with amiodarone treatment, however, given the wide confidence intervals and borderline statistical significance of the trial, larger trials are needed to confirm or refute this view.
Journal ArticleDOI

Evidence-Based Analysis of Amiodarone Efficacy and Safety

TL;DR: This review focuses on the arrhythmias most commonly requiring antiarrhythmic therapy—sustained ventricular tachycardia (VT), ventricular fibrillation (VF), and atrial fibrilation (AF)—because they are the most clinically significant and have been the focus of most studies published.
Related Papers (5)